Zentalis Pharmaceuticals

General Information


We are a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. We use our highly efficient drug discovery engine, which we refer to as our Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that we believe could result in potentially differentiated product profiles. Our discovery engine combines our extensive experience and capabilities across cancer biology and medicinal chemistry.

Employees: 62
Founded: 2014
Contact Information
Address 530 Seventh Avenue, Suite 2201, New York, NY 10018, US
Phone Number (212) 433-3791
Web Address http://www.zentalis.com
View Prospectus: Zentalis Pharmaceuticals
Financial Information
Market Cap $621mil
Revenues $0 mil (last 12 months)
Net Income $-45.7 mil (last 12 months)
IPO Profile
Symbol ZNTL
Exchange NASDAQ
Shares (millions): 9.2
Price range $18.00 - $18.00
Est. $ Volume $165.2 mil
Manager / Joint Managers Morgan Stanley/ Jefferies/ SVB Leerink/ Guggenheim Securities
CO-Managers -
Expected To Trade: 4/3/2020
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change